AU2016335866B2 - Crosslinked particles - Google Patents

Crosslinked particles Download PDF

Info

Publication number
AU2016335866B2
AU2016335866B2 AU2016335866A AU2016335866A AU2016335866B2 AU 2016335866 B2 AU2016335866 B2 AU 2016335866B2 AU 2016335866 A AU2016335866 A AU 2016335866A AU 2016335866 A AU2016335866 A AU 2016335866A AU 2016335866 B2 AU2016335866 B2 AU 2016335866B2
Authority
AU
Australia
Prior art keywords
crosslinked
particles
independently
occurrence
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016335866A
Other languages
English (en)
Other versions
AU2016335866A1 (en
Inventor
Christine Jane ALLEN
Carl Eric ELMQUIST
Frantz Le Devedec
Dean James Rager-Aguiar
Timothy Tordella RUCKH
David Michael STEVENS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2016335866A1 publication Critical patent/AU2016335866A1/en
Application granted granted Critical
Publication of AU2016335866B2 publication Critical patent/AU2016335866B2/en
Priority to AU2021202965A priority Critical patent/AU2021202965B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016335866A 2015-10-09 2016-10-07 Crosslinked particles Active AU2016335866B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202965A AU2021202965B2 (en) 2015-10-09 2021-05-10 Crosslinked particles

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239758P 2015-10-09 2015-10-09
US62/239,758 2015-10-09
US201662281631P 2016-01-21 2016-01-21
US62/281,631 2016-01-21
US201662313013P 2016-03-24 2016-03-24
US62/313,013 2016-03-24
PCT/US2016/056135 WO2017062871A1 (en) 2015-10-09 2016-10-07 Crosslinked particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202965A Division AU2021202965B2 (en) 2015-10-09 2021-05-10 Crosslinked particles

Publications (2)

Publication Number Publication Date
AU2016335866A1 AU2016335866A1 (en) 2018-05-17
AU2016335866B2 true AU2016335866B2 (en) 2021-02-11

Family

ID=58488602

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016335866A Active AU2016335866B2 (en) 2015-10-09 2016-10-07 Crosslinked particles
AU2021202965A Active AU2021202965B2 (en) 2015-10-09 2021-05-10 Crosslinked particles

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202965A Active AU2021202965B2 (en) 2015-10-09 2021-05-10 Crosslinked particles

Country Status (7)

Country Link
US (3) US10258578B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019575B1 (cg-RX-API-DMAC7.html)
JP (3) JP6852079B2 (cg-RX-API-DMAC7.html)
CN (1) CN109843996B (cg-RX-API-DMAC7.html)
AU (2) AU2016335866B2 (cg-RX-API-DMAC7.html)
ES (2) ES2906596T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017062871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019575B1 (en) 2015-10-09 2023-12-06 Le Dévédec, Frantz Crosslinked particles
US11905377B2 (en) 2019-01-17 2024-02-20 Pendant Biosciences, Inc. Factors controlling drug release in cross-linked poly(valerolactone) based matrices
WO2021127623A1 (en) * 2019-12-19 2021-06-24 Pendant Biosciences, Inc. Crosslinked pla-based copolymers
US20250215215A1 (en) * 2022-03-29 2025-07-03 Kaneka Corporation Thermoplastic resin composition
EP4506395A4 (en) * 2022-03-29 2026-04-15 Kaneka Corp CROSS-CUT RESIN PARTICLES AND THEIR PRODUCTION PROCESS
US20250388748A1 (en) * 2022-03-29 2025-12-25 Kaneka Corporation Thermoplastic resin composition
JPWO2025075122A1 (cg-RX-API-DMAC7.html) * 2023-10-04 2025-04-10

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142733A1 (en) * 2007-11-05 2013-06-06 Vanderbilt University Multifunctional degradable nanoparticles with control over size and functionalities

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
CN100546661C (zh) * 2006-12-01 2009-10-07 华南理工大学 一种原位成孔自固化磷酸钙复合组织工程支架的制备方法
US20110274620A1 (en) * 2007-11-05 2011-11-10 Harth Eva M Multifunctional degradable nanoparticles with control over size and functionalities
DK2209496T3 (da) 2007-11-05 2019-08-05 Univ Vanderbilt Multifunktionelle nedbrydelige nanopartikler med kontrol over størrelse og funktioner
CN103003260A (zh) 2009-12-21 2013-03-27 赢创德固赛有限公司 用于制备包含不饱和官能团的环酯的方法和由其制备的聚酯
WO2013169938A2 (en) * 2012-05-08 2013-11-14 Vanderbilt University Polycarbonate containing compounds and methods related thereto
ITTO20130431A1 (it) * 2013-05-28 2014-11-29 Fond Istituto Italiano Di Tecnologia Copolimero e nanoparticelle da esso ottenute per la veicolazione di un farmaco
WO2016174116A1 (en) 2015-04-27 2016-11-03 Eggplant S.R.L. Polyester composition and method for producing the same
EP4019575B1 (en) 2015-10-09 2023-12-06 Le Dévédec, Frantz Crosslinked particles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130142733A1 (en) * 2007-11-05 2013-06-06 Vanderbilt University Multifunctional degradable nanoparticles with control over size and functionalities

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZOU, J et al., "Clicking Well‐Defined Biodegradable Nanoparticles and Nanocapsules by UV‐Induced Thiol‐Ene Cross‐Linking in Transparent Miniemulsions", Advanced Materials, 2011, vol. 23, pages 4274-4277 *

Also Published As

Publication number Publication date
US20190262274A1 (en) 2019-08-29
CA3001329A1 (en) 2017-04-13
EP3359591A1 (en) 2018-08-15
JP7500659B2 (ja) 2024-06-17
AU2016335866A1 (en) 2018-05-17
US20170100343A1 (en) 2017-04-13
CN109843996A (zh) 2019-06-04
EP3359591A4 (en) 2019-05-29
EP4019575A1 (en) 2022-06-29
EP4019575B1 (en) 2023-12-06
ES2973475T3 (es) 2024-06-20
EP3359591B1 (en) 2021-12-01
JP2021102622A (ja) 2021-07-15
CN109843996B (zh) 2022-09-06
WO2017062871A1 (en) 2017-04-13
JP2019500403A (ja) 2019-01-10
US10258578B2 (en) 2019-04-16
AU2021202965A1 (en) 2021-06-03
JP6852079B2 (ja) 2021-03-31
JP2022130727A (ja) 2022-09-06
JP7104198B2 (ja) 2022-07-20
US11426356B2 (en) 2022-08-30
US20230190664A1 (en) 2023-06-22
ES2906596T3 (es) 2022-04-19
AU2021202965B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
AU2021202965B2 (en) Crosslinked particles
US10245244B2 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
WO2019108030A1 (ko) 안정성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
Wischke et al. Controlled drug release from biodegradable shape-memory polymers
JP2023511978A (ja) 外膜又は外膜周囲の神経アブレーションのための徐放性マトリックス及びその使用
Bertram et al. Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF
Sandker et al. Degradation, intra-articular retention and biocompatibility of monospheres composed of [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers
Amani et al. Preparation and pulsatile release evaluation of teriparatide-loaded multilayer implant composed of polyanhydride-hydrogel layers using spin coating for the treatment of osteoporosis
JP2019500403A5 (cg-RX-API-DMAC7.html)
JP2011518812A (ja) チオエステル結合を有するポリマーを含む粒子
CN110051652A (zh) Plga/fk506载药纳米微球及其制备方法和应用
Buwalda et al. In situ forming stereocomplexed and post-photocrosslinked acrylated star poly (ethylene glycol)-poly (lactide) hydrogels
WO2024173668A1 (en) Biodegradable microparticles for sustained drug delivery, methods of preparation and use thereof
HK40009686A (en) Crosslinked particles
HK40009686B (en) Crosslinked particles
US20190134202A1 (en) Liquid Injectable Copolymer
CN105193732A (zh) 雷帕霉素纳米缓释微球及其制备方法
Marques et al. PKPD of PLGA-PEG-PLGA Copolymeric Micelles
CN119744167A (zh) 含有药物和帕莫酸的缓释微球
KV et al. Preparation of Poly-ε-Caprolactone Nanoparticles by Double Emulsion Solvent Evaporation Technique for Ocular Delivery

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)